Health-related quality of life (HRQoL) loss associated with self-perceived anxiety/depression in seropositive rheumatoid arthritis

Objective To analyze the HRQoL loss associated with self-perceived anxiety/depression in patients with seropositive rheumatoid arthritis (RA). Method This secondary data analysis is based on a registry-based retrospective follow-up study of patients with seropositive RA treated between August 2014 a...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Clinical rheumatology 2024-12, Vol.43 (12), p.3647-3655
Hauptverfasser: Rojas-Gualdrón, Diego Fernando, Franco-Salazar, Carolina, Gómez-Henck, Clara Ángela, Manrique-Castrillón, Maria Camila, Hoyos-Méndez, Yennifer Carime, Vélez-Romero, Susana, Díaz-Coronado, Juan Camilo
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Objective To analyze the HRQoL loss associated with self-perceived anxiety/depression in patients with seropositive rheumatoid arthritis (RA). Method This secondary data analysis is based on a registry-based retrospective follow-up study of patients with seropositive RA treated between August 2014 and January 2023 in ARTMEDICA, Colombia. HRQoL loss and self-perceived anxiety/depression were defined as outcomes. Disease activity (DAS-28) and other patient data were also gathered. Statistical analyses were performed using the ordinal logistic and generalized linear regression models. Results A total of 3579 patients with a mean follow-up of 2.9 (SD 2.4) years, 85.6% women with a median age at diagnosis of 48.1 (IQR 37.8–57.5) years, and a median of 6.5 (IQR 1.9–14.7) years living with RA were included. At program admission, the median DAS-28 score was 2.8 (IQR 2.1–4.2), and 6.6% of patients reported extreme anxiety/depression. The average HRQoL loss was 3.4 months per year lived with seropositive AR. Among patients with no pain or discomfort, moderate and extreme anxiety/depression were associated with mean HRQoL losses of 2.2 (95% CI − 2.3 to − 2.2) and 4.1 (95% CI − 4.3 to − 3.8) months. In patients with extreme pain/discomfort, these estimations were 0.8 (95% CI − 0.9 to − 0.7) and 1.9 (95% CI − 2.1 to − 1.7) months, respectively. Conclusion Our study adds to the available body of evidence by clarifying the differential impact of anxiety/depression on HRQoL, depending on the severity of pain. These findings highlight the importance of strengthening mental health care and psychological well-being interventions for patients with RA, regardless of pain or disease activity. Key Points • The average HRQoL loss was 3.4 months per year lived with seropositive AR. • Pain/discomfort rather than disease activity explained the severity of anxiety/depression as well as its associated HRQoL loss. • For patients with extreme pain/discomfort and anxiety/depression, the average HRQoL loss was 8.1 months per year lived with the disease compared to 0.4 months for patients without those impacts.
ISSN:0770-3198
1434-9949
1434-9949
DOI:10.1007/s10067-024-07186-x